Advertisement

Indikationen für frisch gefrorenes Plasma (FFP) und virusinaktivieiertes Humanplasma (VIP)

  • M. Köhler
Conference paper
  • 10 Downloads

Zusammenfassung

FFP ist das am häufigsten angewandte Plasmapräparat in dez Klinik, obwohl vielfach davon ausgegangen wird, daß die Indikation oft nicht streng genug gestellt wird (u.a. Jones, 1987). Seit Januar 1995 ist in Deutschland, wie in anderen europäischen Ländern, nur noch virusinaktiviertes Plasma (VIP) oder Quarantäne-Humanplasma im Verkehr. VIP ist als Solvent/Detergent-VIP (SD) und als Methylenblau-photoxidiertes Plasma (MB) vorhanden. Da durch diese Maßnahme ein deutlich vermindertes infektions-risiko für HIV und Hepatitis angenommen wird, stellt sich die Frage, ob ein erweitertes Indikationsgebeit für diese neuen Präparate vorliegt (Übersicht bei Wieding et al.,1993).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baglin T (1996) Disseminated intravascular coagulation: diagnosis and treatment. Br Med j 312: 683–687Google Scholar
  2. Baudo F, Caimi TM, deCataldo F, Ravizza A, Casella G, Palareti G, Legnani C, Ridolfio L, Biagi R, D’Angelo A, Crippa L, Giudice D, Gallioli E (1995) Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or post surgical complications requiring hemodynamic and/or respiratory support: a controlled, double blind, randomized multicenter study (abstract). Thromb Haemostas 73: 1425Google Scholar
  3. Bell WM, Brain HD, Ness PM, Kickler TS (1991) improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N Engl J Med 325: 398–403Google Scholar
  4. Bertina RM, Koeleman BPC, Koster T et al. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64–67PubMedCrossRefGoogle Scholar
  5. Blauhut B, Lundsgaard-Hansen P (1988) Akuter Blutverlust and Verbrennungen in der operativen Medizin. In: Mueller-Eckhardt C (Hrsg) Transfusionsmedizin. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  6. Blauhut B, Necek S, Vinazzer H, Bergmann H (1982) Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res 27: 271–278PubMedCrossRefGoogle Scholar
  7. Blauhut B, Kramar H, Vinazzer H, Bergmann H (1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39: 81–89PubMedCrossRefGoogle Scholar
  8. Bolton-Maggs PHB, Wensley RT, Kernoff PBA, Kasper CK, Winkelman, L, Lane RS, Smith JK (1992) Production and use of a factor XI concentrate from plasma. Thromb Haemostas 67: 314–319Google Scholar
  9. Brandstätter W, Röse W (1995) Gefrorenes Frischplasma. In: Vorstand und Wissenschaftlicher Beirat der Bundesärztekammer (Hrsg) Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutscher Ärzte-Verlag, Köln, S 53–65Google Scholar
  10. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force (1992) Guidelines for the use of fresh frozen plasma. Transfusion Med 2: 57–63CrossRefGoogle Scholar
  11. Budde U, Drewke E (1993) Veränderungen der von Willebrand Faktor Multimere in Plasmaprodukten (Abstract). Infusionsther Transfusionsmed 20 [Suppl 3]: 50Google Scholar
  12. Bundesgesundheitsamt (1989) Bekanntmachung über die Zulassung and Registrierung von Arznein-mitteln. Monografie: Gefrorenes Frisch-plasma (GFP). Bundesanzeiger 182: 4571 –4572Google Scholar
  13. Consensus Conference (1985) Fresh-frozen plasma. JAMA 253: 551–553CrossRefGoogle Scholar
  14. Colman RW, Hirsh J, Marder VJ, Salzman EW (1994) Haemostasis and thrombosis. Basic principles and clinical practice, 3rd edn. JB Lippincott, PhiladelphiaGoogle Scholar
  15. Council of Europe (1992) Guide to the preparation, use and quality assurance of blood components. StrasbourgGoogle Scholar
  16. Dahlbäck B, Hildebrand B (1994) Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 91: 1396–1400PubMedCrossRefGoogle Scholar
  17. Egbring R, Seitz R (1990) Improved prognosis of fulminant hepatic failure (FHF) after plasma derivative replacement therapy. Enhanced proteolysis of hemostatic proteins confirmed by proteinase-inhibitor complexes determination. Z Gastroenterol 28: 104–109PubMedGoogle Scholar
  18. Fourier F, Chopin C, Huart JJ, RungeI, Caron C, Goudemand J (1993) Double Mind, placebo controlled trial of antithrombin III concentrates in septic shock and disseminated intravascular coagulation. Chest 104: 882–888Google Scholar
  19. Glück D, Kubanek B, Ahnefeld FW (1986) Die Therapie mit Blutkom-ponenten. Voraussetzungen, Indikationen and klinische Anwendung. Infusionsther 13: 240–249Google Scholar
  20. Inbal A, Epstein O, Blickstein D et al. (1993) Evaluation of solvent/detergent-treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis 4: 509–604CrossRefGoogle Scholar
  21. JonesJ (1987) Abuse of fresh frozen plasma [Editorial]. Br Medj 295: 287CrossRefGoogle Scholar
  22. Köhler M (1994) Frisch geforenes Plasma (FFP): Indikationsrichtlinien. In: Lazer G, Höcker P, Köhler M, Mayr WR (Hrsg) Transfusions medizinische Therapiekonzepte zur Blutkomponentensubstitution. Springer, Wien New York, S 430–436Google Scholar
  23. Köhler M, Wieding JU (1994) Virusinaktiviertes Plasma. Infusionsther Transfusionsmed 21 [Suppl 1]: 73 - 76PubMedGoogle Scholar
  24. Lamy M, Eisele B, Keinecke HO, Delvos U, Thijs LG (1996) Bennett D (ed) Antithrombin III in patients with severe sepsis. A randomizedGoogle Scholar
  25. placebo controlled double blind multicenter study. In: Proceedings of the 9th European Congress on Intensive Care Medicine. Monduzzi Editore, Bologna, pp 385–390Google Scholar
  26. Mannucci PM, Franchi F, Dioguardi N (1976) Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet ii: 542–545Google Scholar
  27. Mannucci P M, Federici AB, Sirchia G (1982) Hemostasis testing during massive blood replacement. A study of 172 cases. Vox Sang 42: 113–123PubMedCrossRefGoogle Scholar
  28. Mannucci PM, Bauer KA, Santagostino E, Faioni E, Barzegar S, Coppola R, Rosenberg RD (1994) Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 84: 1314 –1319PubMedGoogle Scholar
  29. Marlar RA, Montgomery RR, Broekmans AW (1989) Report on the diagnosis and treatment of homozygous protein C deficiency. Thromb Haemostas 61: 529–531Google Scholar
  30. Martin JN, Files JC, Blake PG et al. (1990) Plasma exchange for preeclampsia. Am j Obstet Gynecol 162: 126–137PubMedGoogle Scholar
  31. Moake J L (1991) TTP-Desperation, empiricism, progress (Editorial). N Engl J Med 325: 426,–428Google Scholar
  32. Moake J, Chintagumpala M, Turner N, McPherson P, Nolasco L, Steuber C, Santiago-Borrero P, Horowitz M, Pehta j (1994) Solvent/detergent treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 84: 490–497PubMedGoogle Scholar
  33. Mueller-Berghaus G (1989) Pathophysiological and biochemical events in disseminated intravascular coagulation: dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 15: 58 –87CrossRefGoogle Scholar
  34. Pehta J, Sellers P, Horowitz M (1992) Clinical studies with S/D plasma in congenital factor deficient patients [Abstract]. Transfusion 32 [Suppl]: 51Google Scholar
  35. Rock GA, Shumak KH, Buskard NA, Blanchette VS and the Canadian Apheresis Study Group (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325: 393–397Google Scholar
  36. Vinazzer H (1987) Clinical use of antithrombin III concentrates. Vox Sang 53: 193 –198PubMedCrossRefGoogle Scholar
  37. Wieding JU, Hellstern P, Köhler M (1993) Inactivation of viruses in fresh-frozen plasma. Ann Haematol 67: 259–266CrossRefGoogle Scholar
  38. Wieding JU, Unterhalt M, Köhler M (1995a) Accumulation and clearance of methylene blue/light -photooxidized fibrinogen after transfusion of virus-inactivated plasma (Abstract). Ann Hematol 70 (S 1): A84Google Scholar
  39. Wieding JU, Niehues A, Rathgeber J, Zenkér D, Pohl U, Köhler M (1995b) Interim report on a prospective, randomized, controlled clinical study on the efficacy and tolerance of methylene blue/light versus solvent/detergent virus-inactivated plasma (Abstract). Ann Hematol 70 (S 1): A90Google Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • M. Köhler
    • 1
    • 2
  1. 1.Abteilung TransfusionsmedizinUniversitätsklinikum GöttingenBundesrepublik Deutschland
  2. 2.Abteilung TransfusionsmedizinUniversitätsklinikum GöttingenGöttingenBundesrepublik Deutschland

Personalised recommendations